Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
CNY 14.43
(0.42%)
CNY 14.43
(0.42%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 163.13 Million CNY | 225.62% |
| 2022 | 50.09 Million CNY | 150.61% |
| 2021 | 19.99 Million CNY | -24.16% |
| 2020 | 26.35 Million CNY | -80.67% |
| 2019 | 136.38 Million CNY | 226.78% |
| 2018 | 41.73 Million CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | 0.0% |
| 2014 | - CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 271.99 Million CNY | 58.3% |
| 2024 Q1 | 182.54 Million CNY | 14.59% |
| 2024 Q3 | 271.99 Million CNY | 0.0% |
| 2023 Q1 | 85.32 Million CNY | 70.32% |
| 2023 FY | 163.13 Million CNY | 225.62% |
| 2023 Q4 | 163.13 Million CNY | 24.79% |
| 2023 Q2 | 114.32 Million CNY | 33.98% |
| 2023 Q3 | 130.72 Million CNY | 14.35% |
| 2022 Q4 | 50.09 Million CNY | 240.77% |
| 2022 FY | 50.09 Million CNY | 150.61% |
| 2022 Q3 | 14.7 Million CNY | -13.04% |
| 2022 Q1 | 19.81 Million CNY | -0.9% |
| 2022 Q2 | 16.9 Million CNY | -14.66% |
| 2021 Q3 | 10.48 Million CNY | -4.44% |
| 2021 FY | 19.99 Million CNY | -24.16% |
| 2021 Q4 | 19.99 Million CNY | 90.71% |
| 2021 Q2 | 10.96 Million CNY | -10.88% |
| 2021 Q1 | 12.3 Million CNY | -53.31% |
| 2020 FY | 26.35 Million CNY | -80.67% |
| 2020 Q4 | 26.35 Million CNY | -84.68% |
| 2020 Q2 | 171.94 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q3 | 172.05 Million CNY | 0.06% |
| 2019 Q4 | 136.38 Million CNY | 0.0% |
| 2019 FY | 136.38 Million CNY | 226.78% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 FY | 41.73 Million CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2015 FY | - CNY | 0.0% |
| 2014 FY | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |